# CURRICULUM VITAE Akiko Nishiyama

OFFICE ADDRESS:	University of Connecticut Department of Physiology and Neurobiology 75 North Eagleville Road, Unit 3156 Storrs, CT 06269 Phone (860) 486-4561 Fax (860) 486-3303 email <u>akiko.nishiyama@uconn.edu</u> https://pnb.uconn.edu/person/akiko/
	mups.//phb.uconn.edu/person/akiko/

**EDUCATION:** 1984 M.D. Nippon Medical School, Tokyo, Japan; Medicine 1988 Ph.D. Niigata University, Brain Research Institute, Niigata, Japan Neuropathology / Molecular Neurobiology

# APPOINTMENTS:

1988	Research Associate, Brain Research Institute, Niigata University, Japan
1988-91	Postdoctoral Fellow, La Jolla Cancer Research Foundation (currently Sanford
	Burnham Institute, La Jolla, CA
1992	Research Fellow, La Jolla Cancer Research Foundation, La Jolla, CA
1993-94	Research Associate, La Jolla Cancer Research Foundation, La Jolla, CA
1995-98	Project Scientist, Department of Neurosciences, Research Institute, The Cleveland
	Clinic Foundation, Cleveland, OH
1998-2004	Assistant Professor, Department of Physiology and Neurobiology
	University of Connecticut, Storrs, Connecticut
2004-2009	Associate Professor, Department of Physiology and Neurobiology
	University of Connecticut, Storrs, Connecticut
	Professor, Department of Physiology and Neurobiology, University of Conn, Storrs
	Member, University of Connecticut Stem Cell Institute
	Member, University of Connecticut Institute for Systems Genomics
	Member, Connecticut Institute of Brain and Cognitive Sciences
2021-present	Professor and Head, Department of Physiology and Neurobiology, University of
	Connecticut, Storrs

#### Society Membership:

The Society for Neuroscience (since 1993)

Connecticut Academy of Arts and Sciences (since 2010)

(2015~ 2016 Vice President representing University of Connecticut)

Connecticut Academy of Science and Engineering (since 2018)

#### Honors and Awards:

- 1984 Nippon Medical School Alumni Award
- 2015 CLAS Excellence in Research Award, University of Connecticut
- 2023 UConn AAUP (American Association of University Professors) Excellence in Research and Creativity Career Award

# SERVICES: Grant review

Frant reviews:	
2001	Adhoc reviewer, Veterans Affairs Merit Review
2001 - 2002	Adhoc reviewer, NIH BDCN-2
2002	Adhoc reviewer, MS Society for Australia
2002 - 2003	Reviewer of NIH ZRG1 BDCN-2 Study Section

2005	Panel reviewer for NSF Biology
2005 - 2009	Member NIH ZRG1 CNNT study section
2007, 8	Adhoc reviewer, NIH ZRG1 BDCN-2 Study Section
2008	Adhoc reviewer, NIH NSD-C Study Section
2009	Adhoc reviewer, ZRG1 CB-Q 30P Shared Instrumentation
	Adhoc reviewer, ZRG1 BDCN-T (58) R Challenge grants
2010, 2012	Adhoc reviewer for the Royal Society University Fellowship (UK) and Agent
	Nationale de la Recherche (France)
2011	Adhoc reviewer, ZRG1 MDCN-N (02) M
2012	Adhoc reviewer, ZMH1 ERB-M (06)
2012	Adhoc reviewer, International Spinal Research Trust
2013	Adhoc reviewer, International Spinal Research Trust
2013	Adhoc reviewer, ARSEP grant, Foundation ARSEP, France
2013	Adhoc reviewer, DARPA grant (US Army)
2014	Adhoc reviewer, ZRG1 GGG-R (81), ZRG1 GGG-R (80)
2015, 2016	Adhoc reviewer, NIH MDCN N92
2017	Adhoc reviewer, National Multiple Sclerosis Society
2018	Adhoc reviewer, ARSEP grant, France, MRC, UK
2019	Adhoc reviewer, ARSEP grant, France
2020 June	Adhoc reviewer, NIH CMBG (Cell and Molecular Biology of Glia) study section
2021	Adhoc reviewer, Recherche FRC, Wellcome Trust grant
2021 Nov	Adhoc reviewer, NIH ZRG1 MDCN-J (02) study section
2023 April	Adhoc reviewer, Deutsche Forschungsgemeinschaft (German Research
	Foundation) grant
2023 May	Adhoc reviewer, NIH Special Emphasis panel, Clinical Neuroscience;

Editorial board membership and manuscript reviews:

Associate editor, Neuroscience Letters (2016~2022)

Member, Editorial Board, *GLIA* (2011-2018, 2019~), *Dev Neurosci* (since 2013~), *Neuroglia* (2017~2019)

Guest editor: *Neuroscience Letters* Special Issue on Oligodendrocyte Niches in Development and Repair; 2020

Adhoc reviewer for Nature, Nat Neurosci, Nat Commun, Nat Prot, Commun Biol, Sci Rep, PNAS, Cell Rep, Cell Stem Cells, Development, Neuron, J Cell Biol, Oncogene, Physiol Rev, Glia, Neuroglia, J Neurosci, Mol Cell Neurosci, J Neurosci Res, Exp Neurol, Neuroscience, Nature Protocols, Cerebral Cortex, Stem Cells, Frontiers in Neurosci, PLoSONE, Hippocampus, Brain Research, etc.

# **EXTERNAL FUNDING**:

NIH Training Grant (T32 CA09579-03) 1989-1991 1995-1996 Pilot Grant (PP0453; PI: AN) National MS Society 1997-2001 NIH RO1 (NS35136; PI: AN); \$318,429 1998-2002 Research Grant (A2826, PI: AN) National MS Society NIH Shared Instrumentation Grant (1S10RR015684-01) \$196,006 (confocal 2001 microscope) (PI: AN) Pilot Grant, National MS Society (PP0810; PI: AN); A genetic approach to 2001-2002 investigate oligodendrocyte differentiation \$25,000 total direct 2002-2005 Wadsworth Foundation (PI: AN); The role of BDNF in oligodendrocyte-neuron signaling (PI: AN), \$300,000 total direct 2003-2006 Research Grant, National Multiple Sclerosis Society (A2826-B4; PI: AN); The role of NG2 glial cells in remyelination; \$413,475 total direct 2003-2006 NSF Research Grant (0316893, PI: AN); Molecular mechanism of glial progenitor cell differentiation; \$278,450 total direct

2005-2010	NIH (R01 NS049267, PI: AN); Mechanisms of axon-NG2 cell interaction; \$925,000 total direct
2007-2011	Connecticut Stem Cell Program (06SCB03, PI: AN); Optimizing axonal regeneration using a polymer scaffold containing human embryonic stem cells; \$423,897 total direct
2010-2012	NIH (R21 NS 069960, PI: AN); Regulation of glial lineage plasticity by Olig2, \$275,000 total direct
2011-2016	NIH (R01 NS073425, PI: AN); Inflammation and NG2 cell differentiation; \$1,093,750 total direct
2011-2014	Research Grant, National Multiple Sclerosis Society (RG4579A5/1, PI: AN); Promoting remyelination from endogenous NG2 cells; \$93,750 total direct
2012-2017	NIH (R01 NS074870, PI: AN); Heterogeneity of NG2 glial cells; \$1,093,750 direct
2014-2015	NIH (S10OD016435, PI: AN) Leica TCS SP8 FSU AOBS 405 UV Spectral Confocal Microscope; \$456,323
2016-2017	CURE (Citizens United for Research in Epilepsy) Innovator Award (PI: AN); Reprogramming NG2 glial cells into interneurons in an epilepsy model; \$50,000.
2017-2022	NIH (2R01NS073425, PI: AN); Homeostatic regulation of NG2 cell dynamics; \$1,093,750 total direct
2017-2020	NMSS (RG-1612-26501, PI: AN); Neuronal activity-dependent regulation of remyelination and chromatin remodeling. \$555,343 total direct (\$211,000 subcontract to Dr. Maria Cecilia Angulo, CNRS, Paris).
2019-2020	NMSS Pilot Award (PP-1809-32554, PI: AN); VAMP2-mediated exocytosis in NG2 cells is needed for myelination. \$50,000 direct.
2019-2022	Marie Sklodowska-Curie Global Individual Fellowship (845336, PI: Friederike Pfeiffer); The role of NG2 cells in the neural network in health and disease. Subcontract to UConn from Eberhard Karls Universität Tübingen. €19,200.
2020-2025	NIH (R01NS116182, PI: AN), SNARE complex-mediated exocytosis in oligodendrocyte differentiation and survival. \$216,735 annual direct.

# **BIBLIOGRAPHY:**

#### Peer-reviewed journal articles.

1. <u>Nishiyama, A.</u>, Fujii, S., and Sugimoto, K. Observations on the so-called chromaffin cells. Nippon Medical School Journal 48:152-159, 1981.

2. Kumanishi, T., Washiyama, K., Saito, T., <u>Nishiyama, A.</u>, Abe, S., and Tanaka, R. Primary malignant lympoma of the brain: an immunohistochemical study of eight cases using a panel of monoclonal and heterologous antibodies. Acta Neuropathol. 71:109-116, 1986.

3. Abe, S., Shimbo, Y., Saito, T., Kohno, M., <u>Nishiyama, A.</u>, and T. Kumanishi. An immunohistochemical study on "neoplastic angioendotheliosis": demonstration of B lymphocyte markers in the neoplastic cells. Acta Neuropathol. 5:313-316, 1988.

4. Kurihara, T., Takahashi, Y., <u>Nishiyama, A.</u>, and Kumanishi, T. cDNA cloning and amino acid sequence of human brain 2',3'-cyclic nucleotide 3'-phosphodiesterase. Biochem. Biophys. Res. Comm. 152:837-842, 1988.

5. <u>Nishiyama, A.</u>, Saito, T., Abe, S., and Kumanishi, T. An immunohistochemical analysis of T cells in primary B cell malignant lymphoma of the brain. Acta Neuropathol. 79:27-29, 1989.

6. <u>Nishiyama, A.</u>, Onda, K., Washiyama, K., Kumanishi, T., Kuwano, R., Sakimura, K., and Takahashi, Y. Differential expression of glial fibrillary acidic protein in human glioma cell lines. Acta Neuropathol. 78:9-15, 1989.

7. Kumanishi, T., Washiyama, K., <u>Nishiyama, A.</u>, Abe, S., Saito, T., and Ichikawa, T. Primary malignant lymphoma of the brain: demonstration of immunoglobulin gene rearrangements in four cases by the Southern blot hybridization technique. Acta Neuropathol. 79:23-26, 1989.

8. Yoshida, Y., Kumanishi, T., Abe, S., <u>Nishiyama, A.</u>, Yamada, M., and Hinokuma, K. Glomeruloid blood vessels in ethynitrosourea-induced rat gliomas: histological and immunohistochemical studies. Acta Neuropathol. 79:240-247, 1989.

9. Usui, H., Katagiri, T., Yoshida, Y., <u>Nishiyama, A.</u>, Ichikawa, T., Kuwano, R., Takahashi, Y., and Kumanishi, T. In situ hybridization histochemistry of spot 35 protein, a calcium-binding protein, in the rat brain. Mol. Chem. Neuropathol. 14:207-216.3:569-578, 1991

10. <u>Nishiyama, A.</u>, Dahlin, K., and Stallcup, W. B. The expression of NG2 proteoglycan in the developing rat limb. Development 111:933-944, 1991.

11. <u>Nishiyama, A.</u>, Dahlin, K., Prince, J., Johnstone, S., and Stallcup, W.B. The primary structure of NG2, a novel membrane-spanning proteoglycan. J. Cell Biol. 114:359-371, 1991.

12. Stallcup, W. and <u>Nishiyama, A.</u> NG2, a large membrane-spanning proteoglycan. Trends in Glycoscience and Glycotechnology 4:61-70, 1992.

13. Prince, J., <u>Nishiyama, A.</u>, Healy, P., Beasley, L., and Stallcup, W.B. Expression of the F84.1 glycoprotein in the spinal cord and cranial nerves of the developing rat. Dev. Brain Res. 68:193-201, 1992.

14. Kumanishi, T., Usui, H., Ichikawa, T., <u>Nishiyama, A.</u>, Katagiri, T., Abe, S., Yoshida, Y., Washiyama, K., Kuwano R., Sakimura, K., Takahashi, Y., Monoshima, S., Fukuyama, R., and Shimizu, N. Human GFAP: Molecular cloning of the complete cDNA sequence and chromosomal localization (chromosome 17) of the GFAP gene. Acta Neuropathol. 83:569-578, 1992.

15. <u>Nishiyama, A.</u> and Stallcup, W.B. Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol. Biol. Cell 4:1097-1108, 1993.

16. <u>Nishiyama, A., Lin, X.-H., and Stallcup, W.B.</u> Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. Mol. Biol. Cell 6:1819-1832, 1995.

17. <u>Nishiyama, A</u>., Lin, X.-H., Giese, N., Heldin, C.-H., and Stallcup, W.B. Co-localized expression of NG2 proteoglycan and PDGF  $\alpha$  receptor on O2A progenitor cells in the developing rat brain. J. Neurosci. Res. 43:299-314, 1996.

18. <u>Nishiyama, A.</u>, Lin, X-H., Giese, N., Heldin, C-H., and W. B. Stallcup. Interaction between NG2 proteoglycan and PDGF  $\alpha$  receptor on O2A progenitor cells is required for optimal response to PDGF. J. Neurosci. Res. 43:315-330,1996.

19. Yu, M., <u>Nishiyama, A.</u>, Trapp, B.D., and Tuohy, V.K. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 64:91-100, 1996

20. Levine, J.M. and <u>Nishiyama, A.</u> The NG2 chondroitin sulfate proteoglycan: a multifunctional proteoglycan associated with immature cells. Persp. Dev. Neurobiol. 3:245-259, 1996.

21. Trapp, B.D. <u>Nishiyama, A.</u>, Cheng, D. and Macklin, W. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J. Cell Biol. 137:459-468, 1997.

22. <u>Nishiyama, A.</u>, Yu, M., Drazba, J.A. and Tuohy, V.K. Normal and reactive NG2+ glial cells are distinct from resting and activated microglia. J. Neurosci. Res. 48:299-312, 1997.

23. Tillet, E., Ruggiero, F., <u>Nishiyama, A.</u> and Stallcup, W.B. The membrane spanning proteoglycan NG2 binds to collagen V and VI through the central non globular domain of its core protein. J. Biol. Chem. 272:10769-10776, 1997.

24. Burg, M.A., <u>Nishiyama, A.</u>, and Stallcup, W.B. A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Exp. Cell Res. 235:254-264, 1997.

25. Kondo, S., Tanaka, Y., Kondo, Y., Hitomi, M., Barnett, G.H., Ishizaka, Y., Liu, J., Haqqi, T. <u>Nishiyama, A.</u>, Villeponteau, B., Cowell, J.K., and Barna, B.P. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J. 12:801-811, 1998.

26. Grako KA, Ochiya T, Barritt D, <u>Nishiyama A</u>, and Stallcup WB. PDGF a-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J Cell Sci. 112:905-915, 1999.

27. Fang X, Burg MA, Barritt D, Dahlin-Huppe K, <u>Nishiyama A</u>, and Stallcup WB. Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol Biol Cell. 10:3373-87, 1999.

28. Shoshan Y, <u>Nishiyama A</u>, Chang A, Mork S, Barnett GH, Cowell JK, Trapp BD, and Staugaitis SM. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc. Natl. Acad. Sci. USA 96:10361-10366. 1999.

29. <u>Nishiyama A</u>, Chang A, and Trapp BD. NG2+ glial cells: a novel glial cell population in the adult brain. J Neuropathol Exp Neurol. 58:1113-24, 1999.

30. Mathisen PM, Yu M, Yin L, Johnson JM, Kawczak JA, <u>Nishiyama A</u>, and Tuohy VK. Th2 T cells expressing transgene PDGF-A serve as vectors for gene therapy in autoimmune demyelinating disease. J Autoimmunity 13:31-38, 1999.

31. Fuss B, Mallon B, Phan T, Ohlemeyer C, Kirchhoff F, <u>Nishiyama A</u>, and Macklin WB. Purification and analysis of in vivo differentiated oligodendrocytes expressing the green fluorescent protein. Dev Biol 218:259-274, 2000.

32. Wu Q, Miller RH, Ransohoff RM, Robinson S, and <u>Nishiyama A</u>. Elevated levels of the chemokine GRO-1 correlate with elevated oligodendrocyte progenitor proliferation in the jimpy mutant. J Neurosci. 20:2609-2617, 2000.

33. Chang A, <u>Nishiyama A</u>, Peterson J, Prineas J, and Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci. 20:6404-6412, 2000.

34. Bu J, Akhtar N, and <u>Nishiyama A.</u> Transient expression of the NG2 proteoglycan by a subpopulation of activated macrophages in an excitotoxic hippocampal lesion. Glia 34:296-310, 2001.

35. Watanabe M, Toyama Y, <u>Nishiyama A</u>. Differentiation of proliferated NG2-positive glial progenitor cells in a remyelinating lesion. J Neurosci Res 69(6):826-36, 2002.

36. <u>Nishiyama A</u>, Watanabe M, Yang Z, and Bu J. Identity, distribution, and development of NG2+ glial cells. J Neurocytol. 31:437-455, 2002.

37. Watanabe M, Hadzic T\*, and <u>Nishiyama A</u>. Transient upregulation of Nkx2.2 in oligodendrocyte lineage cells during remyelination. Glia 46(3):311-22, 2004. \*undergraduate

38. Bu J, Banki A, Wu Q, and <u>Nishiyama A</u>. Increased NG2+ glial cell proliferation and oligodendrocyte generation in the hypomyelinating mutant shiverer. Glia 48:51-63, 2004.

39. Yang Z, Watanabe M, and <u>Nishiyama A.</u> Optimization of oligodendrocyte progenitor culture methods for enhanced survival. J Neurosci Methods 149(1):50-56, 2005.

40. Asher RA, Morgenstern DA, Properzi F, <u>Nishiyama A</u>, Levine JM, Fawcett JW. Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitro. Mol Cell Neurosci. 29(1):82-96, 2005.

41. <u>Nishiyama A</u>, Yang Z, and Butt AM. Astrocytes and NG2-glia: What's in a name? J Anat. 207(6):687-93, 2005.

42. Yang Z, Suzuki R, Daniels SB, Brunquell CB\*, Sala CJ\*, <u>Nishiyama A</u>. NG2 glial cells provide a favorable substrate for growing axons. J Neurosci. 26(14):3829-39, 2006. \*undergraduate (featured in Journal Club: Barbara Lober. Role of NG2 in Development and Regeneration. J Neurosci. 26(27):7127-7128, 2006)

43. Ziskin JL, <u>Nishiyama A</u>, Fukuya M, Rubio ME, Bergles DE. Vesicular release of glutamate from unmyelinated axons in white matter. Nature Neuroscience. 10(3):321-30, 2007.

44. Wigley R, Hamilton N, Nishiyama A, Kirchhoff F, Butt AM. Morphological and physiological interactions of NG2-glia with astrocytes and neurons. J Anat 210:661-670, 2007

45. Zhu X, Bergles DE, <u>Nishiyama A</u>. NG2 glial cells generate both oligodendrocytes and astrocytes. Development 135(1):145-57, 2008.

46. Zhu X, Hill RA, and <u>Nishiyama A</u>. NG2 cells generate oligodendrocytes and gray matter astrocytes in the spinal cord. Neuron Glia Biology 4(1):19-26, 2008.

47. Komitova M, Zhu X, Serwanski DR, and <u>Nishiyama A</u>. NG2 cells are distinct from neurogenic cells in the subventricular zone. J Comp Neurol 512:702-715, 2009.

48. <u>Nishiyama A</u>, Komitova, M, Suzuki R, Zhu X. NG2 cells (polydendrocytes): multifunctional cells with lineage plasticity. Nature Rev Neurosci 10:9-22, 2009.

49. Barros CS, Nguyen T, Spencer KS, <u>Nishiyama A</u>, Colognato H, Müller U. Beta1 integrins are required for normal CNS myelination and promote AKT-dependent myelin outgrowth. Development. 136(16):2717-24, 2009.

50. Ahn, KH, <u>Nishiyama A</u>, Mierke DF, and Kendall DA. Hydrophobic residues in helix 8 of the cannabinoid receptor 1 are critical for structural and functional properties. Biochemistry. 49(3):502-11, 2010.

51. Trotter J, Karram K, and <u>Nishiyama A</u>. NG2 cells: Properties, progeny and origin. Brain Res Rev 63(1-2):72-82, 2010.

52. De Biase LM, <u>Nishiyama A</u>, and Bergles DE. Excitability and synaptic communication within the oligodendrocyte lineage. J Neurosci 30:3600-11, 2010.

53. Kukley M, <u>Nishiyama A</u>, and Dietrich D. The fate of synaptic input to NG2 glial cells: neurons specifically downregulate transmitter release onto differentiating oligodendroglial cells. J Neurosci 30(24):8320-31, 2010.

54. Wenker IC, Kreneisz O, <u>Nishiyama A</u>, and Mulkey DK. Astrocytes in the retrotrapezoid nucleus sense H+ by inhibition of heteromeric Kir4.1 and Kir-5.1 channels and contribute to chemoreception by purinergic-dependent mechanism. J Neurophysiol 104(6):3042-52, 2010.

55. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, <u>Nishiyama A</u>, Stallcup WB, Berger MS, Bergers G, McKnight TR, Goldman SA, Weiss WA. Non-stem cell origin for oligodendroglioma. Cancer Cell. 18(6):669-82, 2010.

56. Zhu X, Hill RA, Dietrich D, Komitova M, Suzuki R, and <u>Nishiyama A</u>. Age-dependent fate and lineage restriction of single NG2 cells. Development 138:745-753, 2011.

57. Komitova M, Serwanski DR, and <u>Nishiyama A</u>. NG2 cells are not a major source of reactive astrocytes in neocortical stab wound. GLIA 59:800-809, 2011.

58. Hill RA, Natsume R, Sakimura K, and <u>Nishiyama A</u>. NG2 cells are uniformly distributed during barrel cortex development and reorganization. Mol Cell Neurosci 46:689-698, 2011.

59. Butler D, Hwang J, Estick C, <u>Nishiyama A</u>, Kumar SS, Baveghems C, Young-Oxendine HB, Wisniewski ML, Charalambides A, Bahr BA. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS One. 2011;6(6).

60. Moore CS, Milner R, <u>Nishiyama A</u>, Frausto RF, Serwanski DR, Pagarigan RR, Whitton JL, Miller RH, Crocker SJ. Astrocytic tissue inhibitor of metalloproteinase-1 (TIMP-1) promotes oligodendrocyte differentiation and enhances CNS myelination. J Neurosci. 31(16):6247-54, 2011.

61. Feng J, Mantesso A, De Bari C, <u>Nishiyama A</u>, Sharpe PT. Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc Natl Acad Sci U S A. 108(16):6503-8. 2011.

62. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, <u>Nishiyama A</u>, Luo L, Zong H. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146(2):209-21, 2011.

63. Zhu Z, Zuo H, Maher BJ, Serwanski DR, LoTurco JJ, Lu QR, and <u>Nishiyama A</u>. Olig2dependent developmental fate switch of NG2 cells. Development 139:2299-2308, 2012.

64. Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE, Weil RJ, Lee J, <u>Nishiyama A</u>, Bao S. HjelmelanABd, and Rich JN. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev 26(11):1247-62, 2012.

65. Zuo H and <u>Nishiyama A</u>. Polydendrocytes in development and myelin repair. Neurosci Bull 29(2):165-176, 2013.

66. Hill RA, Patel K, Medved J, Reiss A, and <u>Nishiyama A</u>. NG2 cells in white but not gray matter proliferate in response to PDGF. J Neurosci 33(36):14558-14566, 2013.

67. Hill RA and <u>Nishiyama A</u>. NG2 cells (polydendrocytes): listeners to the neural network with diverse properties. GLIA 62(8):1195-2010, 2014.

68. Hill RA, Medved J, Patel K, and <u>Nishiyama A</u>. Organotypic slice cultures to study oligodendrocyte dynamics and myelination. J Vis Exp 90:351835, 2014. PMID: 25177825

69. <u>Nishiyama A</u>, Suzuki R, Zhu X. NG2 cells (polydendrocytes) in brain physiology and repair. Front in Neurosci 8:133, 2014. (PMID: 25018689)

70. Galvao RP, Kasina A, McNeill RS, Harbin JE, Foreman O, Verhaak RG, <u>Nishiyama A</u>, Miller CR, Zong H. Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. Proc Natl Acad Sci U S A 111(40):E4214-23, 2014.

71. Hill RA, Patel K, Goncalves CM, Grutzendler J, and <u>Nishiyama A</u>. Modulation of oligodendrocyte generation during a critical temporal window after NG2 cell division. Nat Neurosci 17(11):1518-1527, 2014. (recommended for F1000 prime, 12/2/2014)

72. <u>Nishiyama A</u>, Boshans L, Goncalves CM, Wegrzyn J, and Patel K. Lineage, fate, and fate potential of NG2-glia. Brain Res. Vol 1638, part B 116-128, May 1, 2016.

73. Serwanski DR, Jukkola P, and <u>Nishiyama A</u>. Heterogeneity of astrocyte and NG2 cell insertion at the node of Ranvier. J Comp Neurol. 525(3):535-552, 2017 (Feb).

74. Tognatta R, Sun W, Goebbels S, Nave KA, <u>Nishiyama A</u>, Schoch S, Dimou L, Dietrich D. Transient Cnp expression by early progenitors causes Cre-Lox-based reporter lines to map profoundly different fates. Glia. 65(2):342-359, 2017 (Feb).

75. Hesp ZC, Suzuki R, Wilson C, <u>Nishiyama A</u>, and McTigue DM. Proliferating NG2+ cells are required for complete glial and fibrotic scar formation, maintenance of tissue integrity, and functional recovery after spinal cord injury in mice. J Neurosci 38(6):1366-1382, 2018 (Feb).

76. Zuo H, Wood W, Sherafat A, Hill RA, Lu QR, and <u>Nishiyama A</u>. Age-dependent decline in fate switch from NG2 cells to astrocytes after Olig2 deletion. J Neurosci 38(9):2359-2371, 2018 (Feb).

77. Serwanski DR, Rasmussen A\*, Perkins S, Brunquell C, and <u>Nishiyama A</u>. Sequential contribution of parenchymal and neural stem cell-derived NG2 cells toward remyelination. Neuroglia 1(1):91-105, 2018 (June). (\*undergraduate student)

78. Welliver RR, Polanco JJ, Seidman RA, Sinha AK, O'Bara MA, Khaku ZM, Santiago González DA, <u>Nishiyama A</u>, Wess J, Feltri ML, Paez PM, Sim FJ. Muscarinic receptor M3R signaling prevents 1 efficient remyelination by human and mouse oligodendrocyte progenitor cells. J Neurosci 38(31):6921-6932, 2018 (August).

79. Gotoh H, Wood WM, Patel KD, Factor DC, Boshans LL, Nomura T, Tesar PJ, Ono K, and <u>Nishiyama A</u>. 2018. NG2 expression in NG2 glia is regulated by binding of SoxE and bHLH transcription factors to a Cspg4 intronic enhancer. GLIA 66(12):2684-2699. (ePub October 2018).

80. Ortiz FC, Habermacher C, Graciarena M, Houry PY, <u>Nishiyama A</u>, Nait Oumesmar B, Angulo MC. 2019. Neuronal activity in vivo enhances functional myelin repair. JCI Insight 4(9):3123434 (May 2, 2019).

81. Boshans LL, Factor DF, Vijender S, Liu J, Zhao C, Mandoiu I, Lu QR, Casaccia P, Tesar PJ, and <u>Nishiyama A</u>. 2019. The chromatin environment around interneuron genes in OPCs and their potential for interneuron reprogramming. Front Neurosci vol 13 article 829, 2019. (August) 2019

82. Boshans LL, Sherafat A, and <u>Nishiyama A.</u> 2020. The effects of developmental and current niches on oligodendrocyte precursor dynamics and fate. Neurosci Lett vol 715:134593, 2020. (Jan 2020). <u>doi: 10.1016/j.neulet.2019.134593</u>

83. Medved J, Wood WM, Van Heyst MD, Sherafat A, Song J-Y, Sakya S, Wright DL and <u>Nishiyama A</u>. 2021. Novel guanidine compounds inhibit platelet-derived growth factor receptor alpha transcription and oligodendrocyte precursor cell proliferation. GLIA 69(3):792-811. (March 2021) <u>doi.org/10.1002/glia.23930</u>

84. Boshans LL, Soh H, Wood WM, Nolan TM, Mandoiu II, Yanagawa Y, Tzingounis AV, <u>Nishiyama A</u>. 2021. Direct reprogramming of oligodendrocyte precursor cells into GABAergic inhibitory neurons by a single homeodomain transcription factor Dlx2. Sci Rep 11(1):3552 (pp1-15). Feb 11. <u>doi: 10.1038/s41598-021-82931-9</u>.

85. <u>Nishiyama A</u>, Shimizu T, Sherafat A, and Richardson WD. 2021. Life-long oligodendrocyte development and plasticity. Sem Cell Dev Biol. 116:25-37. Mar 16. <u>doi:</u> 10.1016/j.semcdb.2021.02.004

86. Sherafat A, Pfeiffer F, Reiss AM, Wood WM, and <u>Nishiyama A</u>. 2021. Microglial Neuropilin-1 trans-regulates oligodendrocyte expansion during development and remyelination. Nat Commun 12(1):2265 (pp1-17) April 15. <u>https://doi.org/10.1038/s41467-021-22532-2</u>

87. <u>Nishiyama A</u>, Serwanski DR, and Pfeiffer F. 2021. Many roles for oligodendrocyte precursor cells in physiology and pathology. Neuropathology 41(3): 161-173. June (epub April 28) <u>https://doi.org/10.1111/neup.12732</u>

88. Pfeiffer F and <u>Nishiyama A.</u> 2021. The impact of fixation on the detection of oligodendrocyte precursor cell morphology and vascular associations. Cells 10(6):1302 (May 24). <u>https://doi.org/10.3390/cells10061302</u>

89. Sherafat A, Pfeiffer F, and <u>Nishiyama A</u>. 2021. Shaping of regional differences in oligodendrocyte dynamics by regional heterogeneity of the pericellular microenvironment. Front Cell Neurosci. <u>doi: 10.3389/fncel.2021.721376</u>

90. Wang J, Yang L, Jiang M, Zhao C, Liu X, Berry K, Waisman A, Langseth AJ, Novitch BG, Bergles DE, Nishiyama A, Lu QR. *Olig2* ablation in immature oligodendrocytes does not enhance CNS myelination and remyelination. J Neurosci. 2022 Nov 9;42(45):8542-8555. DOI: <u>10.1523/JNEUROSCI.0237-22.2022</u>

91. Fekete CD, Nishiyama A. Presentation and integration of multiple signals that modulate oligodendrocyte lineage progression and myelination. Front Cell Neurosci. 2022 Nov 14;16:1041853. DOI: <u>10.3389/fncel.2022.1041853</u>

92. de Blank P, Nishiyama A, López-Juárez A. A new era for myelin research in Neurofibromatosis type 1. Glia. 2023 Jun 29. DOI: <u>10.1002/glia.24432</u>

93. Zeynep M. Altunay<sup>1</sup><sup>•</sup>, Joyshree Biswas<sup>1</sup><sup>•</sup>, Robert S. Pijewski<sup>1,2</sup>, Andrew Tang<sup>1</sup>, Lyndsay C. Kresic<sup>1</sup>, Alexander D. Schouw<sup>1</sup>, Yetunde O. Akinlaja<sup>3</sup>, Brenna C. McAllister<sup>1</sup>, Keaven Caro<sup>1</sup>, Perla A. Peña Palomino<sup>4</sup>, Susanne Ressl<sup>4</sup>, Akiko Nishiyama<sup>3,5</sup>, Stephen J. Crocker<sup>1,5</sup>, David C.

Martinelli<sup>1,5</sup>. C1ql1 expression in oligodendrocyte progenitor cells promotes oligodendrocyte differentiation. GLIA submitted (2023-07-23)

94. Fekete CD, Horning RZ, Doron MS, and Nishiyama A. Cleavage of VAMP2/3 affects oligodendrocyte lineage development in the developing mouse spinal cord. J Neurosci submitted.

95. Friederike Pfeiffer<sup>1,2</sup>, Linda L. Boshans<sup>1</sup>, Colin M. Cleary<sup>1</sup>, Matan S. Doron<sup>1</sup>, Mariapia Grassia<sup>2</sup>, Ulises Arbelo<sup>1</sup>, Sarai Leonardo-Marmol<sup>1</sup>, Daniel K. Mulkey<sup>1</sup>, Akiko Nishiyama<sup>1\*</sup>. Oligodendrocyte precursor cells are an integral part of neural network dynamics associated with collagen VI-rich extracellular matrix remodeling and transforming growth factor beta signaling following neuronal hyperexcitability. Nat Commun submitted.

**Non-peer-reviewed journal articles (Invited review articles) and book chapters** 1. <u>Nishiyama A</u>. 1998. Glial progenitor cells in normal and pathological states. Keio J. Med. 47:105-208. (Lecture given in the Department of Physiology, Keio University, June, 1998).

2. <u>Nishiyama A</u> and Wu Q. 1999. NG2+ glial progenitor cells in normal adult brain and in the dysmyelinating mutant Jimpy. In Keio University Symposia for Life Science and Medicine, vol 2. pp.339-344. Neural Development. Eds. Uyemura K, Kawamura K, and Yazaki T. Springer-Verlag, Tokyo. Proceedings from the second Keio University International Symposia for Life Sciences and Medicine. "Neuroscience: Frontiers of Neural Development", December, 1997.

3. Nishiyama A. 2000. The NG2 proteoglycan. Connective Tissue. 32:39-43.

4. <u>Nishiyama A.</u> 2001. NG2 Cells in the Brain: A Novel Glial Cell Population. Human Cell. 14:77-82, 2001.

5. <u>Nishiyama A</u>. 2007. Polydendrocytes: NG2 cells with many roles in development and repair of the CNS. Neuroscientist. 13(1):62-76, 2007

6. <u>Nishiyama A</u>. 2007. Chapter 4. NG2 proteoglycan and NG2-expressing cells in the nervous system. Neural Proteoglycans. pp51-65. Ed. N Maeda. Research Sign post.

7. Suzuki R and <u>Nishiyama A</u>. Polydendrocytes: lineage and function. Brain and Nerve. 61(7):733-9, 2009. (Japanese)

8. Zhu X, Suzuki R, Zuo H., and <u>Nishiyama A</u>. Oligodendrocyte Progenitor Cell Culture. Chapter 12. Pp217-230. Protocols for Neural Cell Culture. 4<sup>th</sup> ed. Ed. During L. Humana Press. 2010.

9. <u>Nishiyama A</u>. Astrocyte differentiation from oligodendrocyte precursors. Chapter 3. Emerging Concepts in Neuro-Oncology. pp. 41-60, Ed. Colin Watts. Springer-Verlag London. 2013. ISBN 0857294571.

10. <u>Nishiyama A.</u> NG2 cells. Chapter 10. Neuroglia 3<sup>rd</sup> Edition. Ed. Helmut Kettenmann and Bruce Ransom. pp. 109-121. Wiley. 2013. ISBN 0199794596.

11. <u>Nishiyama A</u>, Lee A, and Brunquell CB. Chapter 10. NG2 (Cspg4): Cell surface proteoglycan on oligodendrocyte progenitor cells in the developing and mature nervous system. *In* Neural Surface Antigens. Chapter 9. Pp103-112. Ed. Jan Pruszak. Elsevier. 2015.

12. <u>Nishiyama A</u> and Butt AM. Chapter 8. NG2 cells (Polydendrocytes). *In* "Glial Biology: A Historical Perspective". George DeVries and Anne Boulerne Ed. Wiley-Blackwell. In press.

13. Sherafat MA, Hill RA, and <u>Nishiyama A</u>. Organotypic slice cultures to study oligodendrocyte proliferation, fate, and myelination. Methods in Molecular Biology, edition on "Myelin: Methods and Protocols". Ed Ashwin Woodhoo. Springer. 2018.

14. Guest editor, special issue in *Neuroscience Letters* - Oligodendrocyte niches in development and repair. 13 contributors. To be published 2019-2020.

### INVITED TALKS

1. Structure, Expression, and Function of a Novel Membrane-Spanning Proteoglycan, NG2. Gordon Research Conference on Proteoglycans. July, 1993. (International meeting)

2. NG2+ Glial Progenitor Cells. Gordon Research Conference on Myelin. May, 1996. (Short Talk; International meeting)

3. Enhanced Proliferation of NG2+ Oligodendrocyte Progenitor Cells in the Dysmyelinating Mutant Jimpy is Correlated with Increased Levels of the Chemokine Gro-alpha. Gordon Research Conference on Myelin. February, 1998. (Short Talk; International meeting)

4. Glial Progenitor Cells in Normal and Pathological States. Department of Physiology, Keio University, June, 1998. (Departmental Seminar)

5. Glial Progenitor Cells in Normal and Pathological States. Tokyo Metropolitan Institute of Neurosciences, June, 1998. (Departmental Seminar)

6. Biology of Glial Progenitor Cells that Express the NG2 Proteoglycan. Symposium on New Frontiers in Matrix Biology: The Nervous System. Nagoya, Japan, June, 1999.

7. Glial Cell Proliferation in the Postnatal CNS: Regulation of Proliferation by Chemokines. Department of Neurobiology and Behavior. State University of New York, Stony Brook. March, 2000. (Departmental Seminar)

(internal) Glial Progenitor Cells in the Brain: a Transgenic Approach to Studying their Lineage and Function. Department of Animal Science, University of Connecticut, March, 2000. (Departmental Seminar)

8. NG2 Cells: A Novel Glial Cell Population in the Brain. Human Cell Society XIIIth Fall International Symposium. Niigata, Japan. 2000.

9. The role of NG2 glial progenitor cells in remyelination and neural circuit. Departmental Seminar (Dept of Anatomy). Virginia Commonwealth University, Richmond, VA June, 2001.

(internal) NG2 glial cells: What are they? What do they do? Department of Pharmacy, University of Connecticut, April, 2003. (Departmental Seminar)

(internal) NG2 glia (polydendrocytes): an active member of the neural community. Keynote presentation; UCHC Neuroscience Program Retreat, October 16, 2003.

10. A positive role for NG2 cells in axonal growth. Winter Conference on Brain Research, January, 2004.

11. Identity, differentiation, and morphology of polydendrocytes (NG2 glia). Symposium on Neural stem and progenitor cells. Summer Meeting for the Anatomical Society of Great Britain and Ireland. University College Cork, Ireland. July 6, 2004.

12. NG2 glial cells: what are they and what do they do? Departmental seminar. Neurobiology. Burnham Institute, La Jolla, CA. October 21, 2004.

13. NG2 glial cells: what are they and what do they do? Departmental seminar. Biomedical Sciences. Iowa State University. February 23, 2005.

14. NG2 glial cells: A fourth glial cell population in the mammalian brain. Keynote presentation: Workshop on neuron-glial network. July 2005. Atami, Japan.

15. NG2 glial cells: a physiological role for the fourth glial cell population in the brain. Seminar. Tokyo Metropolitan Institute of Neuroscience. July 2005.

16. The fate of NG2 glia. Session on "A stem cell is a stem cell is an NG2 cell". 40<sup>th</sup> Winter Brain Research Conference. Snowmass, CO. January, 2007.

(internal) The stemness of polydendrocytes / NG2 glial cells and their role in the developing and injured brain. Animal Science 397 Seminar Series, spring 2007. University of Connecticut, Storrs, February 16, 2007

17. NG2 glia: their function and lineage. Tokyo Medical and Dental University. February 28, 2007.

18. NG2 glia (polydendrocytes): their function and lineage. Riken Center for Developmental Biology. Kobe, Japan. March 1, 2007.

19. NG2 cells in the brain: are they multipotential cells or committed glial progenitor cells? Yale School of Medicine (Child Study Center). June 28, 2007.

20. NG2 glia in the brain: their in vivo fate and role in axonal growth. University College London (Department of Physiology), September 3, 2007.

21. Fate of NG2 glia and their role in axonal growth. (organized a Symposium at the Annual Meeting for the Society for Neuroscience, 2007 titled NG2 glia: multifunctional cells exhibiting lineage plasticity.

(internal) NG2 glia (polydendrocytes) in the brain: their in vivo fate and role in axonal growth. University of Connecticut Health Center (Department of Neuroscience), January 8, 2008.

22. NG2 glia: multifunctional cells with lineage plasticity. University of Bonn, Germany. May 2, 2008.

23. The fate of NG2 cells in vivo. Gordon Research Conference on Myelin. May 6, 2008.

24. NG2 Cells in the Brain: Ubiquitous progenitor cells with multiple functions. University of Rochester Medical Center. January, 2009

25. The fate of NG2 cells in vivo. Colloquium at the Annual Meeting for the American Society for Neurochemistry. Charleston, SC. March, 2009. Also organized the session titled 'Regulation of NG2 cell differentiation in development and disease'.

26. Targeting and fate mapping of NG2 glia by BAC transgenesis. Presentation in a symposium titled 'Conditional mutagenesis in glia: technical advances in the selective modulation of astroglial function'. European Glial Meeting in Paris, September, 2009.

27. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. RIKEN Brain Science Institute. May 2010.

28. Age-dependent changes in the astrogliogenic fate of NG2 cells (polydendrocytes). Glial Biology in Medicine, University of Alabama at Birmingham, December 2010.

29. Age-dependent lineage plasticity of NG2 cells (polydendrocytes). Institute of Molecular Biology. University of Oregon, Eugene. April 2011.

30. Age-dependent changes in the astrogliogenic fate potential of polydendrocytes (NG2 cells). International Society for Neurochemistry. Athens, Greece, August, 2011.

31. Age-dependent lineage plasticity of NG2 cells in the brain. Center for Translational Neuroscience. Case Western Reserve University. Cleveland, OH. March 2012.

32. Genetic fate analysis of NG2 glial progenitor cells (polydendrocytes) in the normal and pathological brain. Department of Stem Cell Research and Regenerative Medicine. Lerner Research Institute. Cleveland Clinic Foundation. Cleveland, OH. March 2012.

33. Age-dependent lineage plasticity of NG2 glial progenitor cells in the brain. Connecticut Stem Cell Retreat. Wesleyan University. April 13, 2012.

34. Lineage plasticity of NG2 cells during development and lesion repair. Gordon Research Conference on Myelin. Il Ciocco, Italy, April 2012.

35. Response of polydendrocytes and neural stem cells to demyelinating injury. Institute of Neuropathology of the University Medical Center, Goettingen, Germany, May 21, 2013.

36. Neurizons 2013: Solving the Brain Puzzle – Building Minds from Molecules. "The puzzle of polydendrocytes: what are they and what do they do?" Max-Planck Institute for Biophysical Chemistry, Goettingen, Germany, May 22-25, 2013.

37. Heterogeneity of polydendrocytes and their differentiation dynamics. Physiological Genomics, Ludwig-Maxmillian University, Munich, Germany, May 27, 2013.

38. Regional heterogeneity of NG2 cells (polydendrocytes). Symposium speaker and coorganizer. XIth European Glial Meeting, Berlin, July 2013.

39. NG2 cells: lineage plasticity and dynamics of oligodendrocyte differentiation. Seminar in Molecular Cell Biology, Department of Biology, Johannes Gutenberg University of Mainz, Mainz Germany, July, 2013. Host: Jacky Trotter.

40. NG2 glial cells (polydendrocytes): their fate in development and lesion repair. Department of Neuroscience, University of New Mexico, September 12, 2013.

41. NG2 cell proliferation and dynamics of oligodendrocyte differentiation during development and myelin repair. SUNY Upstate Cell Biology, May 7, 2014.

(internal) NG2 cells (polydendrocytes): Listeners to the neural network with diverse properties. UCHC Neuroscience, May 12, 2014.

42. Chaired session on "Stem cell potential of glia" at the Gordon Conference on Glial Biology, Ventura, CA, March, 2015.

43. NG2 cells in the neural network: How do they respond to signals from other cells? University of Massachusetts Medical, Worcester, MA, January 2016.

44. NG2 glial cells: their fate and function in the neural network. Tokyo Medical University. Tokyo, Japan, February 2016.

45. Chaired session on "Making myelin and myelinating cells" at the Gordon Conference on Myelin, Italy, May 2016.

(internal) Exploring the role of NG2 glial cells in the mouse brain network. UConn IBaCS Meet-and-Speak Event, May 8, 2018, Storrs.

46. The role of microglial Neuropilin-1 in oligodendrocyte development and myelin repair. Second Annual Glial Symposium. Advanced Science Research Center. CUNY Neuroscience Initiative. November 13, 2018.

47. Co-chair (with Brahim Nait-Oumesmar): Session title - Oligodendrocyte diversity and dynamics in development and repair. Symposium title – Cell intrinsic and transactivating mechanisms that regulate NG2 cell dynamics during development and remyelination. XIVth European Meeting on Glial Cell Function in Health and Disease. Porto, Portugal, July 2019.

(Symposium session chair: session title – Oligodendrocyte function in learning and synaptic transmission. 14<sup>th</sup> Biennial ISN/ASN Satellite Meeting on Myelin Biology, St Paulin, Quebec, August 2019.)

(internal) Regulation and function of mouse oligodendrocyte precursor cells. Second UConn Brain Research Symposium. September 20, 2019.

(internal) Critical role of microglial Neuropilin-1 in oligodendrocyte homeostasis. University of Connecticut Health Center Department of Neuroscience. October 3, 2019.

48. The saga of oligodendrocyte precursor cells, whence and whither. Nobel mini-symposium. Nobel Forum, Stockholm. October 9, 2019.

49. Trans-activation of PDGFR on oligodendrocyte precursor cells by microglial Neuropilin-1 – region-specific control of OPC proliferation. University of Wisconsin – Madison, Glia Club seminar. June 24, 2020 (virtual)

50. Region-specific interaction between microglia and oligodendrocyte precursor cells. (keynote address). 42<sup>nd</sup> Annual Meeting of the Japanese Association of Neural Tissue Culture. Niigata, Japan. November 15, 2020. (virtual)

51. Oligodendrocyte precursor cells (NG2 glia) in the brain - what are they and what do they do in the neural network? Trinity College, Undergraduate neuroscience senior seminar, Feb 23, 2021 (virtual, lecture followed by meeting with students).

52. Co-Chair (with Enrica Boda), Session title: Oligodendrocyte progenitor cell fates and interactions with neurons in the adult and developing brain. Symposium title: Dynamic extension of oligodendrocyte precursor cell processes toward active neurons in the hippocampus, XVIth European Meeting on Glial Cells in Health and Disease, Berlin, July 8-11, 2023.

53. Oligodendrocyte precursor cells in the neural network. Departmental of Neurophysiology, University of Tübingen. July 12, 2023.

54. Cincinnati Children's Medical Center. October 25, 2023.

# COURSES TAUGHT

- 1. Molecular and Cellular Neurobiology (3 credit graduate course) 1999-2011.
- 2. Fundamentals of Neuroscience (3 credit graduate course; team-taught) 1999-2001 Neuroanatomy section
- 3. Fundamentals of Neuroscience (3 credit graduate course; team-taught) 2002-2010 Cell biology section
- 4. Developmental Neurobiology (3 credit graduate course; team-taught) 2011- present
- 5. Enhanced Human Physiology and Anatomy (5 credit undergraduate course) 1999-2000.
- 6. Human Physiology and Anatomy (4 credit undergraduate course) 2001 2007.
- 7. Modern Topics in Biology (1 credit, Honors), 2006
- 8. Biology of Nervous System Diseases (3 credit, upper undergraduate) 2008- present
- 9. Principles of Physiology and Neurobiology (5 classes, 3 credit, graduate; team-taught) 2020.

## **ADVISING**

#### **Visiting scholars**

Hitoshi Gotoh (2012-2014) Assist Prof of Biology, Kyoto Prefectural Med Univ Enrica Boda (2015) Assistant Professor RTD in Human Anatomy, Torino University Friederike Pfeiffer (2019-2021) on Marie Sklodowska-Curie Global Individual Fellowship (EU)

#### Postdoctoral fellows supervised

Qian Wu (1997-1998) Professor of Laboratory Medicine, Univ Connecticut Health Center Masahiro Watanabe (2000-2002)Professor of Orthopaedic Surg, Tokai University Hospital, Mila Komitova (2007-2009)

Ryusuke Suzuki (2006-2010) Project Scientist, Cedars Sinai Medical Center, Los Angeles, CA Christopher Brunquell (2013-2014)

Peter Jukkola (2014-2018)Lab supervisor, Anesthesiology, University of PittsburghWilliam Wood (2015-2020)Consultant at B. Riley Financial

#### Other mentoring:

Co-sponsored fellowship applications for:

Virginia Hawkins (postdoc, PNB)

Brenda Milla (graduate student, PNB)

Mentor for K01 grant PI Alejandro Lopez-Juarez (University of Texas Rio Grande Valley)

#### PhD students advised

#### Major advisor:

Zhongshu Yang		99-2005 currently Clinical Assistant Professor in Psychiatry, UC Davis il 2014, currently physician at Kaiser Permanente, Santa Cruz
Xiaogin Zhu		04-2010 currently fellow in Pathology (Univ Mass Med Sch)
Robert A. Hill	20	07-2012 currently Assist Professor, Dartmouth College, Biology.
Hao Zuo	20	06-2012 currently Executive Director, Investment and Development
	De	pt, Chengzhi Shareholding Co., Ltd., Tsinghua Science Park, Beijing
Jelena Medved	20	09-2014 currently postdoc (University of Virginia)
Kiran Patel	20	10-2016 currently postdoc (Yale University)
Alexander Reiss	20	10-2013 (left without a degree, currently res assist at UC San Diego)
Linda Boshans		2013-2020, currently postdoc at MSSM
Christopher Goncalve	es	2014-2015 – transferred to Dr. Daniel Mulkey'
Amin Sherafat		2014-2021
Christopher Fekete		2018-2022
Yetunde Akinlaja		2022-present

Associate advisory	Veeneralated
Associate advisor:	Year completed
Weiwei Li (PNB)	2001
Matthew Sarkisian (PNB)	2002
Jennifer Bendiske (Pharmacy)	2001
Linda Chicoine (Pharmacy)	2002
Byeong-Seon Jeang (Animal Science)	2003
Eric Charych (PNB)	2003
Sean Christie (PNB)	2004
Andrew Doyle (MCB)	2004
James Ackman (PNB)	2004
Jilin Bai (PNB)	2006
Jessica Murphy (PNB)	2008
Sarah (Yoonjung) Chang (PNB)	2008
Mary Lou Lombardi (MCB)	2008
Jie Luo (PNB)	2010
Kasey Baker (PNB)	2011
Julio Mendez (MCB)	2011
Courtney McGinnis (PNB)	2011
Huyn Ahn Kwang (Pharmacy)	2011
Renee Gilberti (MCB)	2011
Brett Shook (PNB)	2012
Fuyi Chen (PNB)	2014
Chris Fiondella (PNB)	has not completed program
Amalia Force (PNB)	left program
Matthew Girgenti (PNB)	left program
Quanzhen Hao (PNB)	2013
Krishna Karunakaran (PNB)	2015
Ashley Kilcollins (PNB)	2017
Mariam Mahmoud (Pharmacy)	2015
Ian Wenker (PNB)	2013
William Wood (MCB)	2015 2012 Ioft and another
Matthew Eastman (PNB)	2012- left program
Megha Sah (PNB)	2016
Zacchary Niday (PNB)	2013-2018
Arpita Biswass (MCB) Anthony Patelunas (MCB)	2013-2017 2014-2016
Wei Shen (PNB)	2014-2020
Fu-shan Kuo (PNB)	2014-2019
Christopher Goncalves (PNB)	2015-2018
Jonathan Choiniere (PNB)	2016-2019
Behnoush Hajian (Pharmacy)	2016-2019
Kyle Drake (PNB)	2018-current
Andrew Beard (PNB)	2018-current
Marybeth Baumgartner (PNB)	2018-2019 (thesis examiner)
Oladimeji Aladelokun (PNB and Medicine)	2018-current
Jesse White (PNB)	2018-2019
Colin Cleary (PNB)	2018-2021
Amanda Harrop (MCB)	2019-current
Daniel Munteaunu (PNB)	2019-2020
Rebecca Oramas (PNB)	2019-current
Julianna Hermann (PNB)	2020-current
Anouk Olthof (PNB)	2018-2020 (proposal and thesis examiner)
Brenda Milla (PNB)	2020-current
Janeth Perez Garza (PNB)	2020-current
Jairo Orea (PNB)	2021-current
. ,	

Emily Parrish-Mulliken (PNB)	2021-current
Russell Howard (MCB)	2021-current

External advisory committee / thesis examiner	
Alison Jennings (University of Western Australia)	2006
Juliette Han (Neurobiology; Harvard Medical School)	2012
Phillip Roth (University of Melbourne, Australia)	2016
Renee Pepper (University of Tasmania, Australia)	2020
Mandy Meijer (Karolinska Institute, Sweden)	2022

# Masters students advised

Major	advisor:

Juan Zeng	2002-2004
Haiyan Wang	2002-2004
Victoria Bagdasaran	2004-2006
Ji Shi	2005-2008
Ryan Wheeler	2008-2010
Anna Heinrich	2016-2018
Zach (Robert) Horning	2016-2020
Elliott Wilion	2021-2022 (left without degree)
Matan Doron	2022-2023 (left without degree)

# Associate advisor:

Sarah Lozano (PNB)	1999
Chetan Naik (PNB)	2006
Richard Lee (PNB)	2006
Sowmya Sridharan (PNB)	2006
Greg Bouchard (PNB)	2006
Sophia Ryzhikov (Pharmacy)	2007
Keith Dlugolenski (PNB)	2008
Sara Pope (PNB)	2010
Zohaib Ikram (PNB)	2012
Anitha Kumar (PNB)	2012
David Ingram (PNB)	2013
Meredith Hailing (PNB)	2013
Siyang Zhou (PNB)	2021
Jiayu Hao (PNB)	2021

#### Undergraduate Students Supervised University Scholars

University Scholars			
Joshua Sheehan	1998-2001	primary care physician at Winchester Hospital, MA	
Joshua Shain	2001-2003	Intern, Grad School of Integrated Medicine, Austin, TX	
Tarik Hadzic	2001-2005	MD PhD 2013, Washington University, St Louis	
		2013- 2017 Resident, Psychiatry, Washington University	
		2017~ Fellow, Pediatric Psychiatry, UCLA	
Christian Colli	2004-2006		
Chris Brunquell	2004-2007	PhD 2012, UC Santa Barbara, CA; postdoc 2013~	
Sagune Sakya	2014-2016	University Scholar award, 2014; PharmD program	
Matan Doron	2020-2022	MS in PNB, UConn	
Presidential Scholar			
Aaron Lee	2006-2010	UCHC MD, now cardiology fellow at Temple Univ.	
Nutmeg Scholar			
Christopher Sala	2003-2006	MD from UCHC 2010, resident at UCHC	
Other honors and non-honors students (2-6 students each year)			
		· - ·	

# **REU summer students supervised**

Corey Cusack	2007
Erin Rasco	2008
Alexandra de la Rocca	2009
Samuel Asinof	2011

# **COMMITTEE SERVICE**

# University committees

- 1. Radiation Safety Committee (2002 2014)
- 2. Institutional Biological Safety Committee (2010 2015, vice chair 2014-5)
- 3. Research Advisory Council (2011 2013)
- 4. Faculty Review Board (2010 2013), Chair 2013
- 5. Faculty Search Committees (2010, 2011 Pharmacy; 2011 Molecular Cell Biology)
- 6. Advisory Committee for Animal Care (2014 present)
- 7. Facility co-Head, Confocal microscope facility, Biotech Bioservices Center (2014 2016)
- 8. Faculty advisor for Advanced Light Microscopy Facility (COR<sup>2</sup>E) (2016 present)
- 9. Review panel for Faculty Large Grants, UCIG grants, Internal Screening for Major Research Instrumentation Grants, Honors Summer Undergraduate Research Fund, CLAS scholarship committee
- 10. College of Liberal Arts and Sciences (CLAS) Dean's Advisory Committee on Promotion, Tenure, and Reappointment (2018-2020)

# **Departmental committees**

- Oversight of PNB confocal facility (2001 2015) Purchased Leica TCS SP2 (2001) and SP8 (2015) Confocal Microscopes for departmental use through NIH Instrumentation Grants.
- Departmental Faculty Search Committees (2000-2001; 2006-7; 2009-10; 2012-3 (chair for a search for 2 positions); 2016-7(EM facility faculty director search), 2019-20
- 3. Search Committee for Confocal Facility Scientist (chair) 2014-5.
- 4. PNB Enhancement Fund Committee (2010~)
- 5. Promotion, Tenure, and Reappointment committee: 2004, 2006, 2009, 2012, 2014, 2017, 2019
- 6. Merit committee: 2001, 2006, 2010, 2012, 2014, 2019
- 7. Graduate Affairs Committee: 2005-2008 (chair 2007-8), 2016-2018
- 8. Coordinator of departmental seminar series (2006-2008)